Of note, despite the extensive research demonstrating the role of IL-17 and interferon (IFN)-γ in promoting inflammation in the gut of IBD patients or the protective role of IL-10, the blockade of IL-17A (8) or IFN-γ (9) as well as the systemic administration of IL-10 (10, 11) has not been beneficial in IBD. The gene discussed is IL17A; the disease is inflammatory bowel disease.